Aetna · Tafamidis ATTR · US health-plan appeal rights

Tafamidis ATTR denied for failing step therapy by Aetna?

Q: How long do I have to appeal a Aetna Tafamidis ATTR denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna Clinical Policy Bulletin — Tafamidis (Vyndaqel/Vyndamax)

The Aetna angle on Tafamidis ATTR

## Why Aetna Applies Step-Therapy to Tafamidis — and Why It May Not Apply Here

Step-therapy (also called "fail-first") policies require that a patient try and fail one or more less-expensive drugs before the insurer will cover the requested agent. For tafamidis in ATTR-CM, step-therapy denials are particularly problematic because tafamidis works through a mechanism — stabilizing the transthyretin tetramer — that is not shared by any currently available generic cardiac drug. Standard heart failure medications address symptoms but do not modify the underlying amyloid deposition. Requiring a patient to "fail" a drug that treats a different pathway before accessing a disease-modifying therapy is clinically incongruent, and many step-therapy denials in this context are successfully overturned.

Additionally, many states have enacted step-therapy override laws requiring insurers to waive step requirements when: (1) the required drug is contraindicated or clinically inappropriate for the patient; (2) the patient already tried and failed the required agent; or (3) delay would cause irreversible harm. Federal parity protections apply to mental health, but state laws vary for specialty drugs — check your state's insurance commissioner website.

## Your Federal Appeal Rights

ACA §2719 External Review: Available after internal denial is upheld, generally within approximately four months. Verify the deadline on your denial notice.
ERISA §503: Full-and-fair review with written criteria and right to submit rebuttal evidence.
Expedited Review: Simultaneously requestable for urgent clinical situations; typically resolved within 72 hours.

## Concrete Appeal Steps and Timeline

1. Obtain the Aetna Clinical Policy Bulletin that triggered the step-therapy requirement — what drug(s) does Aetna require to be tried first? 2. Determine whether the patient has already been on any of those agents (document dates and outcomes). 3. Have the prescriber write a letter explaining why each required step-drug is clinically inappropriate for ATTR-CM (different mechanism, does not address amyloid deposition). 4. File Level 1 internal appeal with that letter, plus diagnosis confirmation and the applicable section of the FDA label for tafamidis. 5. If denied, escalate to Level 2 and then to external IRO review. 6. Simultaneously, check your state's step-therapy override statute and file a state insurance commissioner complaint if applicable.

## Documentation to Gather

Step drug history: Records showing any prior use of the required agents, with dates, doses, duration, and outcome.
Prescriber explanation letter: Why the step drugs are not therapeutically equivalent to tafamidis for ATTR-CM.
Diagnosis confirmation: Testing establishing ATTR-CM subtype (wild-type vs. hereditary variant), relevant to prognosis and urgency.
Guideline citation: Generic reference to ACC/AHA or HFSA society position on ATTR-CM management — your cardiologist should draft this language.

## Criteria-Mapping Structure

List each step drug Aetna requires in column one. In column two, state whether the patient has tried it (with dates/outcomes) or the specific clinical reason it is not appropriate. In column three, cite the supporting record. This matrix format makes the step-therapy override argument self-evident and minimizes back-and-forth with the reviewer.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tafamidis ATTR

Humana denied for failing step therapy of Tafamidis ATTR

Other denial reasons for Aetna Tafamidis ATTR

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.